Moderna Pulling Back on Coronavirus Vaccine Trial Enrollment to Get More Minority Patients Involved

A world eager for progress on vaccines to guard against the SARS-CoV-2 coronavirus and/or COVID-19 might have to wait a bit longer for a breakthrough. The CEO of Moderna (NASDAQ: MRNA), the developer of what many experts consider the leading vaccine candidate, said Friday that his company is slowing enrollment in its crucial phase 3 clinical trial. The reason is that Moderna wants more individuals from minority groups to participate in the study, said Moderna CEO Stephane Bancel in an interview with CNBC.